We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis’ (ABSTRACT NUMBER: L06) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you tell us a little about giant cell arteritis, its prognosis and incidence? (0:05)
- What is the current standard of care for giant cell arteritis, and what are the limitations of this treatment? (1:52)
- What is the mechanism of action of mavrilimumab? (6:07)
Disclosure: Maria Cinta Cid discloses receiving consulting/advisory board fees from GSK, Abbvie and Janssen, lecturing fees from Vifor and a research grant from Kiniksa. Maria Cinta Cid was regional lead for the GiACTA trial (Riche) and co-PI for the KPL-301-C001 trial with mavrilimumab.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Rheumatic Diseases
Clive Kelly, EULAR 2021: Nintedanib in RA-ILD – Findings from the INBUILD Trial
It was a pleasure to meet with Dr Clive Kelly (University of Newcastle-upon-Tyne, Newcastle, UK) to talk around his presentation on ‘Effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in the INBUILD trial.‘ (OP0124), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021. […]
Maria Cinta Cid, ACR 2020 – Mavrilimumab in Patients with Giant Cell Arteritis (Part 2)
We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the results of the phase 2 trial evaluating the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission […]
Rohit Aggarwal, ACR 2020 – Results of the ProDERM Study
We caught up with Rohit Aggarwal to discuss the efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis (Clinical Trial Identifier: NCT02728752). The abstract ‘Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)’ (ABSTRACT NUMBER: 0955) was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!